ID   MOLT-15
AC   CVCL_8150
SY   Molt-15; MOLT 15; BCH-5
DR   BioSample; SAMN03151632
DR   cancercelllines; CVCL_8150
DR   Cosmic; 913415
DR   Cosmic; 1524806
DR   Wikidata; Q54906346
RX   PubMed=2784121;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=9933131;
RX   PubMed=10508494;
RX   PubMed=12592342;
RX   PubMed=15472075;
RX   PubMed=20143388;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a CTV-1 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). Originally thought to originate from a 33 year old male patient suffering from acute myeloid leukemia.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00147.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Gly477Ser (c.1429G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Gly831Glu (c.2492G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Ala353Val (c.1058C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Pro447Leu (c.1340C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Ala500Thr (c.1498G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gly1532Arg (c.4594G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Ser2523Ter (c.7568C>A); Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 8804; PDGFRB; Simple; p.Met772Ile (c.2316G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys656Phe (c.1967G>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Arg75Met (c.224G>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys175Met (c.524A>T); Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1150 ! CTV-1
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=2784121; DOI=10.1002/hon.2900070203;
RA   Drexler H.G., Minowada J.;
RT   "Morphological, immunophenotypical and isoenzymatic profiles of human
RT   leukemia cells and derived T-cell lines.";
RL   Hematol. Oncol. 7:115-125(1989).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10508494; DOI=10.1002/(SICI)1097-0215(19991112)83:4<555::AID-IJC19>3.0.CO;2-2;
RA   MacLeod R.A.F., Dirks W.G., Matsuo Y., Kaufmann M., Milch H.,
RA   Drexler H.G.;
RT   "Widespread intraspecies cross-contamination of human tumor cell lines
RT   arising at source.";
RL   Int. J. Cancer 83:555-563(1999).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//